Apr 12, 2022
OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer [NMSC]).
Mar 15, 2022
OncoBeta® GmbH today announces the first Austrian patients have been treated in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT– for the treatment of non-melanoma skin cancer). Prof. Dr.
Mar 10, 2022
OncoBeta® GmbH has today announced a world-first from Australia, with the first patients treated with Rhenium-SCT® as part of the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of...
Feb 14, 2022
The International Registry is an observational, multicentre, non-interventional program for patients diagnosed with non-melanoma skin cancer (NMSC), to inform treatment outcomes and patterns of care at international hospitals.
Dec 20, 2021
OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies announced today that the company has received ethics approval from the National Health and Medical Research Council (NHMRC) in Australia to begin the...
Nov 23, 2021
An observational, multicentre, international, non-interventional programme to register patients diagnosed with non-melanoma skin cancer (NMSC), to monitor treatment outcomes and patterns of care at international hospitals
Nov 16, 2021
Today OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies for non-melanoma skin cancers (NMSCs), has expanded its offering of non-invasive skin cancer therapy Rhenium-SCT® (Skin Cancer Therapy) in South...